Filing Flows › Health Care › Celldex Therapeutics (CLDX)
Celldex Therapeutics (CLDX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Celldex Therapeutics (CLDX) Q2 2026 earnings results →
Q2 2026 Revenue down 97% year over year to $22K
Celldex Therapeutics made $22K in Q2 2026 (-97% Y/Y): Contracts and grants $15K, Product development and licensing agreements $7K. Operating margin n/m, net loss $73.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $22K in Q2 2026, down 97% year over year and up 47% from the previous quarter. Contracts and grants was the largest line at 68% of revenue. Contracts and grants lost $708K year over year (down 98%), 100% of the total change.
Operating costs exceeded revenue by $80.6M, an operating margin of -366468.2%. Total costs grew 25% against a revenue fall of 97%. The fastest-growing cost line was General & admin (+26%). The quarter ended with a net loss of $73.5M, narrower than the previous quarter's $78.7M loss.
Operating cash flow was −$57.4M. Non-cash charges added back $902K of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items added $6.8M. Capital expenditures of $3.2M exceeded it, leaving free cash flow of −$60.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $22K | -97% | n/m | −$73.5M | −$57.4M |
| Q1 2026 | 10-Q | May 7, 2026 | $15K | -98% | n/m | −$78.7M | −$65.6M |
| Q4 2025 | 10-K | Feb 25, 2026 | $121K | -90% | n/m | −$81.3M | −$63.9M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $730K | -71% | n/m | −$56.6M | −$44.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $695K | +346% | n/m | −$53.8M | −$54.4M |
| Q4 2024 | 10-K | Feb 27, 2025 | $1.2M | -72% | n/m | −$47.1M | −$32.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Celldex Therapeutics
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
In its own words, from its 10-K, filed Feb 25, 2026.
Celldex Therapeutics against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -97% against the peers' median +2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CLDX Celldex Therapeutics | Q2 2026 | $22K | -97% | n/m |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Celldex Therapeutics 10-Q on SEC EDGAR · CIK 744218 · In Vitro & In Vivo Diagnostic Substances
13F: who owns CLDX and who is buying
More on CLDX
- How Celldex Therapeutics makes money: revenue by segment
- Celldex Therapeutics next earnings date and what analysts expect
- Celldex Therapeutics stock forecast, price target and fair value
- Who owns Celldex Therapeutics stock: holders, funds and Congress trades
- Celldex Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results